No “clear and consistent evidence” of difference in inhibitor risk

There is no clear and consistent evidence of a difference in the incidence of inhibitor development between factor VIII products derived from plasma and those made by recombinant DNA technology. The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency has now completed its review of factor VIII medicines to evaluate the risk of …